¾ÏÀ» À§ÇÑ Àΰø Ç×ü Ä¡·á
Engineered Antibody Therapeutics for Cancer
»óǰÄÚµå : 1532332
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 71 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

±â¼úÀÇ ¹ßÀü°ú 1µî±Þ Á¦¾àȸ»çÀÇ °ü½É Áõ°¡·Î Àΰø Ç×ü ¼ºÀå ÃËÁø

ÀÌ Á¶»ç´Â ¾Ï¿¡ ´ëÇÑ Àΰø Ç×ü Ä¡·áÀÇ ÃâÇöÀ» ºÐ¼®ÇÏ°í ±× Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù. ´ÜŬ·ÐÇ×üÀÇ ÇѰè·Î ÀÎÇØ »õ·Î¿î Æ÷¸Ë¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ÀÌÁ߯¯À̼º, »ïÁ߯¯À̼º µî ´ÙÁ߯¯À̼º Ç×ü¿Í Fab, VHH¿Í °°Àº Ç×ü Á¶°¢À» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àΰø Ç×ü´Â ¿©·¯ Ç¥Àû¿¡ µ¿½Ã¿¡ °áÇÕÇÏ¿© ´õ ³ôÀº È¿°ú¸¦ ¹ßÈÖÇϰí Á¾¾ç ³»¼ºÀ» ±Øº¹ÇÒ ¼ö ÀÖµµ·Ï ¸¸µé¾îÁ³½À´Ï´Ù. Çõ½ÅÀûÀÎ ¿£Áö´Ï¾î¸µ ±â¼úÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº ¹Ý°¨±â ¿¬Àå, ¸é¿ª¿ø¼º °¨¼Ò µî ´õ ³ªÀº PK/PD¸¦ ´Þ¼ºÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Àΰø Ç×ü¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇØ 1µî±Þ Á¦¾à»çµéÀº ÁÖ¿ä °³¹ß»çµé°ú Çù·ÂÇÏ¿© ´ÙƯÀ̼º Ç×ü¸¦ Æ÷Æ®Æú¸®¿À¿¡ Ãß°¡ÇÏ¿© Ä¡·á Àü¹®¼ºÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. °³¹ß»çµéµµ AI/ML ±â¹Ý ±â¼ú Á¦°ø¾÷ü¿Í Á¦ÈÞÇÏ¿© Ç×ü °ø±ÞÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç´Â ´Ù¾çÇÑ Ç×ü Æ÷¸ËÀ» ½Äº°Çϰí Áúº´ ºÐ¾ß¿¡¼­ÀÇ Àû¿ë °¡´É¼ºÀ» °ËÁõÇÕ´Ï´Ù. Àΰø Ç×ü Æ÷¸ËÀÇ °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ Çõ½ÅÀûÀÎ Ç×ü ¹ß°ß, ¿£Áö´Ï¾î¸µ ¹× °³¹ß ¼­ºñ½º¸¦ °³¹ßÇÏ´Â ÁÖ¿ä ¾÷üµéÀ» ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ¾ÏÀ» À§ÇÑ Àΰø Ç×ü Ä¡·áÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀΰú ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ» °ËÅäÇϰí, ½ÃÀå ÁøÀÔÀÚ ¹× ÀÌÇØ°ü°èÀÚ°¡ Ȱ¿ëÇÒ ¼ö ÀÖ´Â ÀÌ ºÐ¾ßÀÇ º¯È­·Î ÀÎÇÑ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù.

¸ñÂ÷

Àü·«Àû ¿øÄ¢

¼ºÀå ±âȸ ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ

ÁøÈ­ÇÏ´Â Àΰø Ç×ü Ä¡·á »óȲ

Ç×ü ¹ß°ß°ú °³¹ß

ÀÌÇØ°ü°èÀÚ ½Ã½ºÅÛ

¼ºÀå ±âȸ À¯´Ï¹ö½º

ºÎ·Ï

´ÙÀ½ ½ºÅÜ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and VHH. These engineered antibodies are created to have heightened efficacy and overcome tumor resistance by binding to multiple targets simultaneously. Innovative engineering technologies are helping researchers achieve better PK/PD with an enhanced half-life and less immunogenicity. The demand for engineered antibodies is also driving Tier I pharmaceuticals to collaborate with key developers to expand their therapeutic expertise by adding multispecific antibodies to their portfolios. Developers, on their part, are partnering with AI/ML-based technology providers to enhance their antibody offerings.

The study identifies the different antibody formats and examines their applicability across disease areas. It looks at the key players developing innovative antibody discovery, engineering, and development services to facilitate the creation of engineered antibody formats. The study examines the factors driving and restraining the growth of engineered antibody therapeutics for cancer and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key Questions This Study Answers

1. What are the key drivers and restraints in the development of engineered antibodies?

2. What are the applications of engineered antibodies across different disease areas? What are the key focus areas of R&D efforts?

3. Which disease areas are seeing increased adoption?

4. What are the key innovative discoveries and engineering technologies?

5. What does the funding landscape look like?

Table of Contents

Strategic Imperatives

Growth Opportunity Analysis

Growth Generator

Evolving Landscape of Therapeutic Engineered Antibodies

Antibody Discovery and Development

Stakeholder System

Growth Opportunity Universe

Appendix

Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â